ASH 2018 | Role of FLT3 inhibitors as maintenance following transplant in AML

Name: Role of FLT3 inhibitors as maintenance following transplant in AML
Uploaded: 2018-12-06T12:57:53.000Z
Duration: 2 min 46 s
Description: Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the role of FLT3 inhibitors as a maintenance therapy following transplant in acute myeloid leukemia (AML).

Mark Levis • 6 Dec 2018

ASH 2018

Acute Myeloid Leukemia Leukemia Midostaurin Sorafenib

Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the role of FLT3 inhibitors as a maintenance therapy following transplant in acute myeloid leukemia (AML).